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Background. Increasing international migration may challenge healthcare providers unfamiliar with acute
and long latency infections and diseases common in this population. This study deﬁnes health conditions encoun-
tered in a large heterogenous group of migrants.
Methods. Migrants seen at GeoSentinel clinics for any reason, other than those seen at clinics only providing
comprehensive protocol-based health screening soon after arrival, were included. Proportionate morbidity for syn-
dromes and diagnoses by country or region of origin were determined and compared.
Results. A total of 7629 migrants from 153 countries were seen at 41 GeoSentinel clinics in 19 countries.
Most (59%) were adults aged 19–39 years; 11% were children. Most (58%) were seen >1 year after arrival; 27%
were seen after >5 years. The most common diagnoses were latent tuberculosis (22%), viral hepatitis (17%), active
tuberculosis (10%), human immunodeﬁciency virus (HIV)/AIDS (7%), malaria (7%), schistosomiasis (6%), and
strongyloidiasis (5%); 5% were reported healthy. Twenty percent were hospitalized (24% for active tuberculosis
and 21% for febrile illness [83% due to malaria]), and 13 died. Tuberculosis diagnoses and HIV/AIDS were
reported from all regions, strongyloidiasis from most regions, and chronic hepatitis B virus (HBV) particularly in
Asian immigrants. Regional diagnoses included schistosomiasis (Africa) and Chagas disease (Americas).
Conclusions. Eliciting a migration history is important at every encounter; migrant patients may have acute
illness or chronic conditions related to exposure in their country of origin. Early detection and treatment, particu-
larly for diagnoses related to tuberculosis, HBV, Strongyloides, and schistosomiasis, may improve outcomes. Policy
makers should consider expansion of refugee screening programs to include all migrants.
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The speed and magnitude of international human mobility
results in changes in global disease patterns that pose chal-
lenges to migrants, who may carry diseases with them, and
healthcare professionals, who may be unfamiliar with these
diseases [1, 2]. Migrants are at higher risk for certain infec-
tious diseases with long latency periods, many amenable to
screening, and for which identiﬁcation and treatment may
reduce long-term morbidity and mortality [3–5]. Clinicians
caring for migrants in developed countries note higher rates
of latent tuberculosis, chronic hepatitis B virus (HBV) infec-
tion, intestinal parasites, and malaria [4, 6–9]. Therefore,
healthcare professionals must be aware of issues pertaining to
screening, diagnostics, and treatment for diseases that are not
endemic. This can be challenging, particularly with shifting
patterns of migration and resultant changes in disease
epidemiology.
GeoSentinel sites are specialized travel or tropical medicine
clinics that collect clinician-based surveillance data on travel–
related diseases. This study analyzed the spectrum of infec-
tious diseases and acute medical problems in migrants
resettled internationally and evaluated for speciﬁc health con-
cerns, comparing results by origin region. The data provide
clinicians caring for heterogenous groups of migrants a
snapshot of common acute and chronic conditions affecting
migrants. Health issues of migrants seen for systematic, proto-
col-based health screening in 2 US-based GeoSentinel clinics
that perform such screening are described in a companion
paper [10]. Together, these studies inform public health pro-
fessionals by adding data useful in developing policy that
might reduce health disparities in migrants.
METHODS
Data Source
The GeoSentinel Surveillance Network (http://www.istm.org/
geosentinel/main.html) currently consists of 54 member sites,
in 24 countries over 6 continents. Patients are eligible for in-
clusion in the database if they crossed an international border
and sought medical care at a GeoSentinel clinic. Sites use best
reference diagnostic testing available and document inpatient
or outpatient status, major complaint(s), and identify the
country of acquisition of the illness based on itinerary, incuba-
tion period, and/or known epidemiology. GeoSentinel sites
enter anonymous questionnaire-based information into a
central structured query language database. The GeoSentinel
data collection protocol was classiﬁed at the Centers for
Disease Control and Prevention (CDC) as exempt public
health surveillance after review by the institutional review
board (IRB). At other sites, human studies approval was ob-
tained if required by local IRBs.
Inclusion and Exclusion Criteria
All individuals whose last or only purpose of travel was for
migration and who visited a GeoSentinel clinic from March
1997 through November 2009 were included. Migrants seen at
GeoSentinel clinics providing only comprehensive, protocol-
based health screening soon after reaching their ﬁnal destina-
tion country were excluded, but their data have been analyzed
and presented separately [10].
Deﬁnitions
Migrants are individuals who crossed international borders for
the purpose of resettlement. Children were deﬁned as age ≤18
years. Country of origin was deﬁned based on a combination
of country of birth, country of residence for most of the ﬁrst
10 years of life, and citizenship, with the goal of capturing the
country in which the migrant was likely to have had the most
prolonged exposures. Countries were grouped into 13 GeoSen-
tinel-deﬁned regions. Final diagnoses were assigned from a
standardized list of >500 diagnoses, categorized into 29 broad
syndrome groups [11]. The database requires at least 1 diagno-
sis, which may be “no morbidity reported,” but allows all diag-
noses identiﬁed in a single patient to be reported.
Statistical Analysis
Data were analyzed using SAS software, version 9.1 (SAS Insti-
tute). Proportionate morbidity was calculated as number of
migrants with a speciﬁc diagnosis or group of diagnoses as a
proportion of all migrants from a speciﬁc country or region of
origin. Diagnoses were summarized using syndrome group-
ings, with details of the most common speciﬁc diagnoses. Dif-
ferences between groups used χ2 test or Fisher exact test as
appropriate. To adjust for the large number of tests per-
formed, P < .01 was considered statistically signiﬁcant.
RESULTS
Patient Population
Of the 15 421 migrant records from GeoSentinel clinics identi-
ﬁed, 7629 (49.5%) migrants who were not seen at clinics that
provide systematic protocol-based screening were included in
this analysis. These predominantly nonrefugee migrants were
seen at 41 GeoSentinel clinics on 5 continents in 19 countries,
including Canada (33% of migrants), Europe (32%), United
States (15%), and Australia and New Zealand (13%) (see Sup-
plementary Table 1). Migrants originated from 153 countries;
an origin country could not be determined for 87 (1%).
Almost one-third originated from 6 countries: Burma
(Myanmar), Ethiopia, Somalia, Sudan, India, and Bolivia
(Figure 1). East Africa, Southeast Asia, West Africa, and South
Asia each accounted for ≥10% of the migrants.
926 • CID 2013:56 (1 April) • McCarthy et al
Most (59%) were adults aged 19–39 years; 11% were chil-
dren, and 7% were aged ≥60 years. Age and sex distribution
varied by region (see Supplementary Figure 1). Southeast
Asian migrants were older than those from many other
regions. Females represented 46% of the overall study popula-
tion; however, migrants from West Africa (34%) and North
Africa (32%) were less likely, and those from South America
more likely (54%), to be female.
Figure 1. Top contributing countries of origin in referred migrants (N = 7629; percentage overall). Other = Albania, Algeria, Angola, Argentina,
Armenia, Azerbaijan, Barbados, Belarus, Benin, Bhutan, Bosnia, Bulgaria, Burkina Faso, Cape Verde, Central African Republic, Chad, Chile, Columbia,
Comoros, Cook Islands, Costa Rica, Croatia, Cuba, Czech Republic, Djibouti, Dominica, El Salvador, Equatorial Guinea, Gabon, Gambia, Georgia,
Grenada, Guatemala, Guinea Bissau, Guyana, Honduras, Hong Kong, Hungary, Indonesia, Iran, Israel, Jamaica, Jordan, Kazakhstan, Kenya, South Korea,
North Korea, Kosovo, Kuwait, Kyrgyzstan, Laos, Lebanon, Libya, Lithuania, Macedonia, Madagascar, Malawi, Malaysia, Mali, Martinique, Mauritania,
Mauritius, Micronesia, Moldova, Mongolia, Mozambique, Namibia, Nepal, New Caledonia, Nicaragua, Niger, Oman, Palestinian Territories, Papua New
Guinea, Paragauy, Peru, Poland, Puerto Rico, Qatar, Reunion, Russia, St Kitts and Nevis, St Lucia, St Vincent and Grenadines, Samoa, Saudi Arabia,
Serbia, Singpore, Slovakia, Solomon Islands, South Africa, Suriname, Swaziland, Syria, Taiwan, Tajikstan, Tanzania, Tibet, Timor-Leste, Tonga, Trinidad
and Tobago, Tunisia, Turkey, Turkmenistan, Uganda, Ukraine, United Arab Emirates, Uruguay, Uzbekistan, Venezuela, Yemen, Zambia.
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Medical Conditions of Migrants
The most common diagnoses were latent tuberculosis (22%),
acute and chronic viral hepatitis (17%), active tuberculosis
(10%), malaria (7%), HIV/AIDS (7%), schistosomiasis (6%),
and strongyloidiasis (5%); 5% had no health condition
reported.
Table 1 shows the top 10 infectious diagnoses for adults
and children. Speciﬁc diagnoses by region of origin are shown
in Table 2. Of the 1515 (20%) patients who were hospitalized,
364 (24%) had active tuberculosis and 264 (17%) had malaria.
Diagnoses of noninfectious diseases were reported in 1144 mi-
grants (15%). There were 13 deaths, related to AIDS (3), tu-
berculosis (3), AIDS and tuberculosis coinfection (1), cerebral
malaria (1), Strongyloides hyperinfection (1), African trypano-
somiasis (1), visceral leishmaniasis (1), pneumonia (1), and
unknown causes (1).
The interval between migration and presentation varied by
region of origin and diagnosis (Figure 2); most (58%) mi-
grants were seen >1 year after resettlement, and 27% >5 years
later. Few (9%) were seen within the ﬁrst 3 months of arrival..
Those presenting within 90 days of arrival most often re-
ported fever (41%), gastrointestinal symptoms (21%), or an
abnormal laboratory test (20%), whereas those seen after 90
days most often presented with an abnormal lab test (39%) or
gastrointestinal symptoms (26%). Respiratory symptoms were
reported in 10%–13% of migrants at all time periods. Skin and
genitourinary complaints were uncommon. Overall, 18%–25%
of those seen in any time period beyond 30 days after arrival
had no reported symptoms, while only 11% of those seen
within 30 days had no reported symptom.
Figure 2 shows the top diagnoses in migrants from Africa,
Latin America, Asia, and Eastern Europe by time to presenta-
tion at a GeoSentinel site. Latent tuberculosis was diagnosed
in at least 10% of migrants from each of these regions at every
time interval and active tuberculosis at every time interval;
chronic hepatitis B was diagnosed in all time intervals with a
striking increase in number of cases diagnosed in migrants
from Asia ≥5 years after resettlement; and HIV/AIDS was diag-
nosed from all regions in all time intervals. Several conditions
were prominent in a single region, including schistosomiasis
(Africa), Chagas disease and neurocysticercosis (Latin
America), and hepatitis C and echinococcus (Eastern Europe).
Strongyloidiasis was frequent in all regions except Eastern
Europe. The large proportion of “other” diagnoses in Latin
American and Eastern European migrants reﬂects the diversity
of diagnoses in migrants from these regions.
Tuberculosis
One-third of migrants had a tuberculosis diagnosis (latent or
active disease). Latent tuberculosis (24% of adult and 11% of
childhood diagnoses) was the most common diagnosis record-
ed from almost every region during almost all time periods.
Active tuberculosis was reported in 11% of adults and 7% of
children, with most (67%) detected >1 year after migration,
and 29% after ≥5 years. Pulmonary tuberculosis was reported
as frequently as extrapulmonary tuberculosis, except among
migrants from South Asia and East Africa, in whom extrapul-
monary tuberculosis was signiﬁcantly more likely (P = .014).
Blood-borne Pathogens
Chronic HBV was the second most commonly reported diag-
nosis in adults (847 [11%]), with most cases (73%) diagnosed
> 1 year after arrival, and 41% diagnosed after >5 years. Hepa-
titis C virus was diagnosed in 5% of all migrants but in 10%
of adults aged >40 years. Although most cases were from Asia
(140 [5%]) and Africa (140 [4%]), the region with the highest
proportion of cases was Eastern Europe (37 [12%]). There
were 34 cases of acute hepatitis (16 hepatitis A; 18 hepatitis
B), without a relationship to country of origin. For 11 cases (5
hepatitis A, 6 hepatitis B), the reported time after resettlement
exceeded the expected incubation periods, suggesting undis-
closed travel or local transmission. Most hepatitis A cases (10/
16 [63%]) occurred in children, whereas most acute HBV
cases (15/18 [83%]) were found in those aged 19–29 years
(median, 27 years).
Table 1. Ten Most Frequent Infectious Disease Diagnoses in
Referred Migrants, Children and Adults
Diagnosis Frequency Percentage
Children (age ≤18 y; n = 854)
Malaria 170 20.0
Latent tuberculosis 92 10.8
No health condition identified 82 10.0
Schistosomiasis 71 8.3
Giardiasis 67 7.8
Active tuberculosis 65 7.6
Hepatitis B, acute and chronic 41 4.8
Strongyloidiasis 40 4.7
Eosinophilia 25 2.9
Intestinal ascaris 19 2.2
Adults (age ≥19 y; n = 6751)
Latent tuberculosis 1619 24.0
Hepatitis B, acute and chronic 864 12.8
Active tuberculosis 723 10.7
Human immunodeficiency virus/AIDS 510 7.6
Schistosomiasis 370 5.5
Hepatitis C 346 5.1
Strongyloidiasis 344 5.1
No health condition identified 326 4.8
Malaria 321 4.8
Eosinophilia 182 2.7
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There were 526 cases of HIV/AIDS reported, primarily in
adults aged <40 years. The highest proportions of cases were
in migrants from Africa (370 [11%]); 329 were asymptomatic,
24 presented with acute febrile illness, and 176 met the deﬁni-
tion for AIDS.
Malaria
Malaria was reported in 7% of migrants, with the greatest pro-
portion in migrants from Southeast Asia (20%) and West
Africa (12%). Malaria was the most frequent diagnosis in chil-
dren (20%) and was reported less commonly in adults aged
>39 years (47/2230 [2%]). The majority of malaria cases (85%;
Plasmodium falciparum [58%] and Plasmodium vivax [36%])
were seen within 3 months of arrival. Of the 98 cases seen >3
months after arrival, 45 were P. vivax (46%) and 30 were
P. falciparum (31%). Nine individuals were diagnosed with
malaria >5 years after migration (3 P. falciparum, 2 P. vivax, 2
Plasmodium ovale, 2 Plasmodium malariae, and 1 unknown).
Other Selected Infections
Schistosomiasis was diagnosed in 370 of 2804 migrants from
Africa (13%); although 48% were diagnosed in the ﬁrst year,
cases continued to be diagnosed up to 10 years after arrival.
Strongyloidiasis, reported in approximately 5% of both adults
and children, was one of the most common diagnoses in all
regions. Nine migrants had Strongyloides hyperinfection syn-
drome (2% of reported cases); 5 were from Asia. Of note, 4
were seen >10 years after resettlement, including one reported
50 years after arrival. There were 137 cases (2 children) of
neurocysticercosis; most were from the Americas (107); with
Table 2. Speciﬁc Infectious Diagnoses by Region of Origina
All Regions East Africa
Southeast
Asia
West
Africa
South
Asia
South
America
North
Africa
P ValueDiagnosis (N = 7629) (n = 1253) (n = 1200) (n = 1048) (n = 844) (n = 698) (n = 503)
Tuberculosis 2503 (33) 472 (38) 388 (32) 252 (24) 350 (41) 163 (23) 210 (42) <.0001
PPD+ (latent
tuberculosis)
1715 (22) 273 (22) 302 (25) 162 (5) 168 (20) 125 (18) 173 (34) <.0001
Active tuberculosisb 790 (10) 199 (16) 86 (7) 90 (9) 183 (22) 38 (5) 37 (7) <.0001
Tuberculosis,
extrapulmonary
434 (6) 123 (10) 45 (4) 49 (5) 122 (14) 18 (3) 15 (3) <.0001
Tuberculosis,
pulmonary
397 (5) 91 (7) 45 (4) 48 (5) 68 (8) 21 (3) 24 (5) <.0001
Viral hepatitis 1266 (17) 215 (17) 267 (22) 159 (15) 90 (11) 20 (3) 111 (22) <.0001
Hepatitis B (acute,
chronic, or
asymptomatic
carrier)
906 (12) 148 (12) 196 (16) 143 (14) 43 (5) 16 (2) 80 (16) <.0001
Hepatitis C (acute or
chronic)
357 (5) 75 (6) 73 (6) 15 (1) 39 (5) 5 (1) 25 (5) <.0001
Systemic febrile 786 (10) 50 (4) 294 (25) 204 (19) 74 (9) 27 (4) 11 (2) <.0001
Malaria 496 (7) 26 (2) 241 (20) 126 (12) 38 (5) 5 (1) 6 (1) <.0001
Gastrointestinal–other 965 (12) 163 (13) 148 (12) 134 (13) 75 (9) 90 (13) 72 (14) <.0001
Strongyloidiasis 384 (5) 49 (4) 91 (7) 52 (5) 24 (3) 36 (5) 29 (6) <.0001
HIV/AIDS 526 (7) 184 (15) 53 (4) 102 (10) 9 (1) 31 (4) 12 (2) <.0001
Schistosomiasis 442 (6) 133 (11) 12 (1) 123 (12) 2 (0) 3 (0) 114 (23) <.0001
Misc. tissue parasitec 350 (5) 24 (2) 6 (1) 18 (2) 19 (2) 185 (26) 26 (5) <.0001
No health conditions
identified
409 (5) 44 (4) 43 (4) 51 (5) 42 (5) 117 (17) 11 (2) <.0001
Inpatient care 1515 (20) 233 (19) 223 (19) 336 (32) 241 (29) 70 (10) 92 (18) <.0001
Data are presented as No. of migrants (%) in each region. P < .01 was considered statistically significant.
Abbreviations: HIV, human immunodeficiency virus; Misc., miscellaneous; PPD, purified protein derivative.
a Origin regions not shown (n = 2087) include Caribbean, Central America, Central Asia, Eastern Europe, Central Africa, Northeast Asia, Oceania, southern Africa,
Western Asia, and unknown origin.
b Includes 42 patients with both pulmonary and extrapulmonary tuberculosis.
c Includes filariasis, Chagas disease, extraintestinal ascaris, cysticercosis, nonhepatic echinococcosis, trichinella, visceral larva migrans, and visceral
leishmaniasis.
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the rest from Asia (17), Africa (10), and Eastern Europe (3);
46% were reported >5 years after migration. Other infections
seen predominantly more than a year after arrival included
Chagas disease (170 cases) in migrants from Bolivia; ﬁlariasis
(145 cases) primarily in adults from Africa; echincoccosus (99
cases) primarily in adults from South Asia, Eastern Europe
and West Asia; and leprosy (81 cases), primarily in older pa-
tients from South Asia. Acute diarrhea, dermatological illness,
and respiratory illness were infrequent diagnoses.
DISCUSSION
The top infectious diagnoses in this heterogeneous group of
migrants to 41 countries included tuberculosis (both latent
and active disease), chronic hepatitis (B and C), strongyloidia-
sis, and regionally important infectious diseases such as schis-
tosomiasis (Africa) and chronic Chagas disease. These data
emphasize the need for health professionals to consider
migration-related diagnoses and to take the opportunity
during any medical encounter to screen migrants for infec-
tions with potential for long-term and even life-threatening
sequelae. The same health problems for which screening is
currently recommended among refugee populations continue
to be of concern for nonrefugee migrants many years after re-
settlement [12, 13].
The results emphasize the important of reactivation and of
complications from initially asymptomatic infections, includ-
ing active tuberculosis, Strongyloides hyperinfection syndrome,
and sequelae of hepatitis B and C. These might have been pre-
vented if addressed early in the resettlement period. The data
suggest and the authors support expanding current refugee-
centric preventive medical approaches to include additional
migrants. Unlike the US-bound migrants [10] receiving sys-
tematic protocol-based evaluation, the vast majority of these
migrants did not undergo routine predeparture screening or
public health interventions, nor did they have comprehensive
Figure 2. Top diagnoses by region of origin shown by time from arrival. A, Africa (n = 3275). B, Asia (n = 2713). C, Latin America (n = 1232*).
D, Eastern Europe (n = 305). Sixty percent of the patients seen within 3 months were reported with a wide variety of diagnoses. Abbreviations: HIV,
human immunodeﬁciency virus; LTBI, latent tuberculosis; TB, tuberculosis.
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postarrival evaluations. These comprehensive programs, cur-
rently reserved for groups such as US resettling refugees, can
signiﬁcantly reduce health impact of infectious disease in
migrant populations [13]. Expansion of such programs inter-
nationally should be strongly considered on health grounds;
however, we recognize the policy challenges posed to individ-
ual receiving nations, including up-front screening costs and
regulatory changes.
Tuberculosis is an important health concern [14, 15],
and many nonendemic countries report a disproportionate
burden of active tuberculosis among foreign-born residents,
particularly within the ﬁrst 2–5 years of arrival but extending
for their lifetime [16–21]. The frequent diagnosis of latent tu-
berculosis (22%) is consistent with other studies reporting
high proportions of migrants with latent tuberculosis (20%–
70%) [8, 22]. However, our data may be an underestimate, as
these migrants did not all undergo systematic latent tuberculo-
sis screening.
Screening for chronic hepatitis is important to reduce mor-
bidity and mortality in individual migrants, but is also an op-
portunity to prevent transmission by, for example, providing
hepatitis B vaccination to close contacts. Recent reviews have
documented increased risk of chronic hepatitis morbidity in im-
migrants and refugees, as well as the cost-effectiveness of
screening and treating chronic HBV infections in migrants [23].
The CDC recommends HBV screening for all migrants from
countries with >2% hepatitis B prevalence.
The proportion of migrants with intestinal parasites, 11%
overall, was less than in other publications [24, 25], possibly
reﬂecting detection or referral bias, asymptomatic nature of
some infections, lack of systematic screening, time since mi-
gration, and/or socioeconomic heterogeneity of the study
population. Three parasitic infections, however, were found in
speciﬁc migrant groups and these data suggest that migrants
from these groups should be assessed for these infec-
tions at any health encounter. Schistosomiasis may result in
chronic hepatic, renal, and genitourinary disease. Strongyloides
infection is particularly important to diagnose and treat
owing to the potential for life-threatening dissemination, with
risk persisting even decades after migration, especially if
the infected migrant develops comorbidities requiring or
resulting in immunosuppression [7, 26, 27]. Chagas disease
can result in cardiac and gastrointestinal disease years after
migration, and may be passed from infected women to their
infants.
Symptomatic malaria was a concern early after migration,
with most cases presenting within 3 months [28, 29]. The 9
cases reported >5 years after arrival are unusual, though
delayed symptomatic malaria, including P. falciparum, has
been reported [30]. We could not rule out unreported travel in
these cases. It is important to note the disproportionate
burden of malaria in migrant children, particularly from
Africa.
A number of hospital admissions may have been prevent-
able if there had been earlier diagnosis and management of
conditions such as tuberculosis, HIV, and strongyloidiasis;
most deaths were from potentially preventable or treatable
conditions.
This study has a number of limitations, including both de-
tection and referral bias. GeoSentinel clinics are selected
because of expertise in travel and immigrant medicine, and
their clinicians may be more likely to perform additional
testing on at-risk migrants. An example is Bolivian migrants
in Spain who are tested for Chagas disease. In some clinics,
patients with latent tuberculosis may be tested routinely for
HIV infection. There is potential for testing bias based on
site- or region-speciﬁc factors dictating where and how mi-
grants ﬁnd their way to a particular clinic. It is not possible
from our dataset to separate the conditions diagnosed by se-
lective screening from those diagnosed as a result of clinical
presentation or referral.
GeoSentinel clinics see a small fraction of migrants world-
wide, and therefore the data may not be generalizable to all
migrant groups worldwide. The results reﬂect proportionate
morbidity of a population of migrants presenting to GeoSenti-
nel clinics, rather than prevalence data. These are surveillance
data and are limited by lack of detailed diagnostic information;
for example, it is not possible to determine how many of those
with HBV experienced complications of the infection. Most
GeoSentinel clinics report infectious diseases; noninfectious
health problems are not sought or reported systematically and
have not been included in this analysis. Another limitation is
inability to identify time of acquisition of the reported diseases
or conditions. For some conditions, such as strongyloidiasis,
hepatitis, and tuberculosis, we cannot completely eliminate the
possibility of transmission after migration, but given the epi-
demiology in receiving countries, it is unlikely and would have
limited impact on the ﬁndings. Finally, some migrants may
have undisclosed postmigration travel and so time to presenta-
tion may be misleading.
Despite these limitations, these data expand on and differ
from previous publications for several reasons: data are from
many countries and migrant groups (not just refugees), and
many migrants were seen more than a year after resettlement.
Most publications related to immigrant health focus on the
immediate postmigration period [4, 6, 7]. Although refugees
generally make up <10% of migrants, they are overrepresented
in published data because they have an organized migration,
including medical screening and presumptive treatment pro-
grams [12–14, 31].
Migration will likely continue at the same or a greater rate,
challenging healthcare providers, medical educators, and
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policy makers to adapt to the evolving epidemiology. Most im-
migration entry criteria concentrate on immediate public
health risk of migrants on the receiving country and not long-
term health risk to the migrant. In this study, many of the
public health diseases of concern could have been detected
and addressed earlier in the migration process, perhaps reduc-
ing both the impact on the healthcare system and the burden
of disease in individual migrants. Addressing health needs of
migrants requires policies that are responsive to changing epi-
demiology and that take into account regions of origin.
Mapping of areas of settlement within receiving countries may
help to tailor support and recommendations, and provide im-
proved education for the receiving medical community.
CONCLUSIONS
These results suggest important steps for policy makers and
healthcare professionals. Policy makers should advocate for
evidence-based, standardized approaches to comprehensive
predeparture and postarrival health programs for all migrants
at risk. Greater integration of migration health in medical
school curricula is needed. Providers should utilize the oppor-
tunity to screen for latent infections that have a higher preva-
lence in globally mobile patients, including latent tuberculosis,
HBV, and Strongyloides, and, where appropriate, schistosomia-
sis and Chagas. In addition, they must be aware of existing
large numbers of foreign-born individuals well established in
host countries, for whom migration-related health risks must
be considered. A medical encounter for any reason is a chance
to address possible exposures by asking “Where were you
born, where have you lived, and where have you traveled?”
Unless medical care is approached consistently through the
lens of globally mobile populations, migrants will continue to
experience health disparities as they present with unaddressed
migration-related conditions.
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